1 / 4

Impact of Axl siRNA on Luciferase Activity and Cell Viability in Cancer Studies

This study investigates the effect of Axl siRNA on luciferase activity and cell viability using BaF3 cells. Multiple Axl-targeting siRNA constructs were tested, with measurements of relative luminescence units (RLU) recorded. The findings highlight variations in luciferase expression post-transfection with Axl-2 and Axl-4 siRNAs. Additionally, the sensitivity of BaF3 cells to Gas6 and AxlFc treatment was evaluated, providing insights into Axl's role in aiding cell survival and proliferation. The data may have implications for cancer therapeutics targeting the Axl pathway.

margie
Télécharger la présentation

Impact of Axl siRNA on Luciferase Activity and Cell Viability in Cancer Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Luciferase siRNA No 1st Ab Axl siRNA 800000 700000 600000 500000 RLU 400000 300000 200000 100000 0 not transfected GL2 Axl-4 D-3 D-4 GL2 Fig.1. A. Axl-2 Axl-4 D-1 D-2 D-3 D-4 B. 300 Luc ferase GL2 i si RNA i 250 f or w ard : CGU ACG CGG AAU ACU UCG ATT r everse: UCG AAG UAU UCC GCG UAC GTT 200 Dhar m ac o n - 1 MFI 150 for w ard : GAA AGA AGG AGA CCC GTT ATT r everse: TAA CGG GTC TCC TTC TTT CTT 100 Dhar m ac o n - 2 for w ard : CCA AGA AGA TCT ACA ATG GTT 50 reverse: CCA TTG TAG ATC TTC TTG GTT Dhar m ac o n - 3 0 GL2 Axl-2 Axl-4 D-1 D-2 D-3 D-4 no 1st Ab for w ard : GGA ACT GCA TGC TGA ATG ATT C. reverse: TCA TTC AGC ATG CAG TTC CTT Dhar m ac o n - 4 for w ard : GAA GGA GAC CCG TTA TGG ATT reverse: TCC ATA ACG GGT CTC CTT CTT A x l - 2 for w ard : GAC ATC CTC TTT CTC CTG CTT reverse: GCA GGA GAA AGA GGA TGT CTT A x l - 4 for w ard : GAT TTG GAG AC ACA CTG ATT reverse: TCA GTG TGT TCT CCA AAT CTT

  2. Fig.2. 10 Axl-4 Dkk3 Ang-2 1 GL2 Axl DKK3 Fold of change Ang-2 -10 -100 siRNA

  3. Axl -actin BaF3 BaF3/Axl D. 350000 300000 250000 RLU 200000 150000 100000 50000 0 sup 7C3 3C7 6A8 4F8 3B3 2C9 8B5 7B4 7D5 6G2 3G9 3G4 13F6 3C12 8F11 2B10 12A11 13H10 control AxlFc (200ng/ml) Fig.3. A. B. C. 120 250000 100 200000 80 RLU Viability(%) 150000 BaF3 60 BaF3 Axl 100000 40 50000 20 0 0 12.5 25 50 100 200 0 0 0.1 0.25 0.5 1.25 2.5 Gas6 (ng/ml) AxlFc (g/ml)

  4. Fig.4. A. human Axl.ECD.His mouse Axl.Fc B. 3 2.5 2 control OD450nm 4F8 8B5 1.5 12A11 3G9 1 0.5 0 huAxl.Fc huMer.fc huTyro.Fc Antigen concentration (10ug/ml)

More Related